• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 29.37
  • VXN 2.82
  • VXO 33.70
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)

Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

Company Profile

Enzo Biochem, Inc., a life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Enzo Life Sciences, Enzo Clinical Labs, and Enzo Therapeutics. The Enzo Life Sciences segment manufactures, develops, and markets functional biology and cellular biochemistry products and tools to research and pharmaceutical customers. It offers products applied in the fields of antibiotics, autophagy, cancer, cell cycle, cell death, cell signaling, cell trafficking, genomics/molecular biology, immunology, inflammation, lipid signaling, neurobiology, protein degradation, ROS/RNS, and stress/heat shock. The Enzo Clinical Labs segment offers routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It also operates a full-service clinical laboratory, a network of 30 patient service centers, a stand alone or rapid response laboratory, and a full-service phlebotomy department. The Enzo Therapeutics segment engages in the research and development of various therapeutic drug candidates based on cell signaling, immune regulation, and gene regulation for the treatment of gastrointestinal, infectious, ophthalmic, and metabolic diseases. Enzo Biochem, Inc. sells its products through direct sales force and distributors in the United States, Switzerland, the United Kingdom, Belgium, and Germany. The company was founded in 1976 and is headquartered in New York, New York.

ENZ (Enzo Biochem Inc)
Last Trade 2.47 Date 3/28/2020
Change % -0.41 % Price Change -0.01
Open 2.44 52 Week High 0.0
High 2.59 52 Week Low 0.0
Low 2.32 Type stock
Volume 525203 Average Volume 102071
Prev Close 2.48 Stock Exchange NYSE
Bid 2.3 Ask 2.47
Bid Size 5 Ask Size 1
1st Yr Estimated EPS Growth 2nd Yr Estimated EPS Growth
2 Years Forward Earning Yield 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share 1.49 Book Value Yield 0.6032
Buy Back Yield CAPE Ratio
Cash Return 0.1075 Cash Flow per Share 0.2432
Cash Flow Yield 0.0985 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield 0.0121 EV/EBIT
EV/EBITDA EV / Free Cash Flow 9.2999
EV / Forward EBIT EV / Forward EBITDA
EV / Forward Revenue EV / Pre Tax Income 60.38
EV / Revenue 1.1621 EV / Total Asset 0.7978
Expected Dividend Growth Rate Free Cash Flow per Share 0.2102
Free Caash Flow Ratio 11.749882 Free Cash Flow Yield 0.0851
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio 75.54903 Payout Ratio 0.0
PB Ratio 1.657738 PB Ratio 10 Year Growth -0.02996
PB Ratio 3 Year Growth 3.06886 Cash Ratio 3 Year Average 430.7307
Price to Cash Flow Ratio 10.156197 PEG Payback
PEG Ratio PE Ratio 82.333333
PE Ratio 10 Year Average 37.274647 PE Ratio 10 Year Growth
PE Ratio 10 Year High 142.5 PE Ratio 10 Year Low 5.226804
PE Ratio 1 Year Avg 85.472249 PE Ratio 1 Year High 142.5
PE Ratio 1 Year Low 52.4 PE Ratio 3 Year Avg 58.154116
PE Ratio 5 Year Avg 37.274647 PE Ratio 5 Year High 142.5
PE Ratio 5 Year Low 5.226804 Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg 137.529811 Price Change 1 Month 1.159624
Price to Cash Ratio 2.28083 Price / EBITDA
Price to Sales Ratio 1.468186 Price to Sales Ratio 10 Year Growth -0.050127
Price to Sales Ratio 3 Year Avg 2.56075 Price to Sales Ratio 5 Year Avg 37.274647
Sale per Share 1.6823 Sales Yield 0.6811
Sustainable Growth Rate 0.0223 Tangible Book Value per Share 1.3175
Tangible Book Value per Share 3 year Avg 1.5227 Tangible Book Value per Share 5 year Avg 1.3944
Total Asset per Share 2.4556 Total Yield
Working Capital per Share 1.0072 Working Capital per Share 3 Year Avg 1.2929
Working Capital per Share 5 Year Avg 1.1938 Beta 1.497478